Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 2, 1999, Pages 739-748

  Pollack, Vincent A ^a   Savage, Douglas M ^a   Baker, Deborah A ^a   Tsaparikos, Konstantinos E ^a   Sloan, Donald E ^a   Moyer, James D ^a   Barbacci, Elsa G ^a   Pustilnik, Leslie R ^a   Smolarek, Teresa A ^a   Davis, John A ^a   Vaidya, Madhur P ^a   Arnold, Lee D ^a,b   Doty, John L ^a   Iwata, Kenneth K ^a,c   Morin, Michael J ^a  

^a PFIZER INC   (United States)

^b BASF Bioresearch Corporation   (United States)

^c OSI PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[6,7 BIS(2 METHOXY ETHOXY)QUINAZOLINE 4 YL](3 ETHYNYLPHENYL)AMINE; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHOTYROSINE; QUINAZOLINE DERIVATIVE; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MIXTURE; FEMALE; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CELL DIVISION; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; PHOSPHORYLATION; PHOSPHOTYROSINE; POLYPHARMACY; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TYROSINE;

EID: 0032695910     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J and Sela M (1988) Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80:1605-1611.
2. Ahn NG, Weiel JE, Chan CP and Krebs EG (1990) Identification of multiple epidermal growth factor-stimulated protein serine/threonine kinases from Swiss 3T3 cells. J Biol Chem 265:1187-1194.
3. Arnold LD and Schnur RC (1998) Alkynyl and azido-substituted 4-anilinoquinazoline derivatives are potent inhibitors of the erbB family of oncogenic and proto-oncogenic protein tyrosine kinase(s), useful for treating hyper-proliferative disorders. US Patent 5,747,498.
4. Baselga J and Mendelsohn J (1994) The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 29:127-138.
5. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH and Mendelsohn J (1993) Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327-1333.
6. Bertics PJ and Gill GN (1985) Self-phosphorylation enhances the protein-tyrosine kinase activity of the epidermal growth factor receptor. J Biol Chem 260:14642-14647.
7. Bier H, Hoffmann T, Haas I and van Lierop A (1998) Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 46:167-173.
8. Bjorge JD, Chan TO, Antczak M, Kung HJ and Fujita DJ (1990) Activated type I phosphatidylinositol kinas is associated with the epidermal growth factor (EGF) receptor following EGF stimulation. Proc Natl Acad Sci USA 87:3816-3820.
9. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR and Tortora G (1996) Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 88:1770-1776.
10. Copp BR, Fairchild CR, Cornell L, Casazza AM, Robinson S and Ireland C M (1998) Naamidine A is an antagonist of the epidermal growth factor receptor and an in vivo active antitumor agent. J Med Chem 41:3909-3911.
11. Dean C, Modjtahedi H, Eccles S, Box G and Styles J (1994) Immunotherapy with antibodies to the EGF receptor. Int J Cancer Suppl 8:103-107.
12. Di Fiore, PP, Pierce JH, Fleming TP, Hazan R, Ullrich A, King CR, Schlessinger J and Aaronson SA (1987) Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51:1063-1070.
13. Fan Z, Baselga J, Masui H and Mendelsohn J (1993a) Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53:4637-4642.
14. Fan Z, Masui H, Atlas I and Mendelsohn J (1993b) Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 53:4322-4328.
15. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S and Dobrusin EM (1998) Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 95:12022-12027.
16. Geran RI, Greenberg NH, Macdonald MM, Schumacher AM and Abbott BJ (1972) Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 3:1-104.
17. Gullick WJ (1991) Prevalence of aberrant expression of the epidermal growth factor. Br Med Bull 47:87-98.
18. Halberg F, Haus E, Lardoso SS, Scheving LE, Kuhl JFW, Shiotsuka R, Rosene G, Pauly JE, Runge W, Spaulding JF, Lee JK and Good RA (1973) Toward a chronotherapy of neoplasia: Tolerance of treatment depends upon host rhythms. Experientia 29:909-934.
19. 2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci USA 79:4761-4765.
20. Honegger AM, Kris RM, Ullrich A and Schlessinger J (1989) Evidence that autophosphorylation of solubilized receptors for epidermal growth factor is mediated by intermolecular cross-phosphorylation. Proc Natl Acad Sci USA 86:925-929.
21. Honegger AM, Szapary D, Schmidt A, Lyall R, Van Obberghen E, Dull TJ, Ullrich A and Schlessinger J (1987) A mutant epidermal growth factor receptor with defective protein tyrosine kinase is unable to stimulate proto-oncogene expression and DNA synthesis. Mol Cell Biol 7:4568-4571.
22. Kunkel MW, Hook KE, Howard CT, Roberts BJ, Przybranowski S, Elliott WL and Leopold WR (1996) Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs 13:295-302.
23. Magni M, Pandiella A, Helin K, Meldolesi J and Beguinot L (1991) Transmembrane signalling at the epidermal growth factor receptor. Positive regulation by the C-terminal phosphotyrosine residues. Biochem J 277 (Pt 2):305-311.
24. Margolis B, Bellot F, Honegger AM, Ullrich A, Schlessinger J and Zilberstein A (1990) Tyrosine kinase activity is essential for the association of phospholipase C-gamma with the epidermal growth factor receptor. Mol Cell Biol 10:435-441.
25. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G and Mendelsohn J (1984) Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44:1002-1007.
26. Masui H, Moroyama T and Mendelsohn J (1986) Mechanism of anti-tumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res 48:5592-5598.
27. McLeod HL, Brunton VG, Eckardt N, Lear MJ, Robins DJ, Workman P and Graham MA (1996) In vivo pharmacology and anti-tumour evaluation of the tyrphostin tyrosine kinase inhibitor RG13022. Br J Cancer 74:1714-1718.
28. Modjtahedi H, Eccles S, Box G, Styles J and Dean C (1993a) Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Br J Cancer 67:254-261.
29. Modjtahedi H, Styles J, Box G, Eccles S, Gusterson B and Dean C (1993b) Antitumour activity of rat Mabs to the human receptor for EGF, in Mutant Oncogenes: Targets for Therapy? (Epenetos AA and Lemonie NR eds) pp 35-47, Chapman and Hall, London.
30. Modjtahedi H, Styles J and Dean C (1993c) The growth response of human tumour cell lines expressing the EGF receptor to treatment with EGF and/or Mabs that block ligand binding. Int J Oncol 3:237-243.
31. Moolenaar WH, Bierman AJ, Tilly BC, Verlaan I, Defize LH, Honegger AM, Ullrich A and Schlessinger J (1988) A point mutation at the ATP-binding site of the EGF-receptor abolishes signal transduction. EMBO J 7:707-710.
32. Moyer JD, Barbacci EG, Iwata K, Arnold L, Boman B, Cunningham A, DiOrio C, Doty J, Morin MJ, Moyer MP, Neveu M, Pollack VA, Pustilnik LR, Reynolds MM, Sloan D, Theleman A and Miller P (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838-4848.
33. Mueller BM, Romerdahl CA, Trent JM and Reisfeld RA (1991) Suppression of spontaneous melanoma metastasis in seid mice with an antibody to the epidermal growth factor receptor. Cancer Res 51:2193-2198.
34. Neal DE, Benett MK, Hall RR, Marsh C, Abel PD, Sainsbury JRC and Harris AL (1985) Epidermal growth factor receptor in human bladder cancer: Comparison of invasive and superficial tumors. Lancet 1:366-368.
35. Nishibe S, Wahl MI, Hernandez-Sotomayor SM, Tonks NK, Rhee SG and Carpenter G (1990) Increase of the catalytic activity of phospholipase C-gamma 1 by tyrosine phosphorylation. Science 250:1253-1256.
36. Ozanne B, Richards CS, Hendlen R, Burns D and Gusterson B (1986) Overexpression of the EGF receptor is a hallmark of squamous cell carcinoma. J Pathol 149:9-14.
37. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Barbacci EG, Pustilnik LR, Smolarek TA, Davis JA, Vaidya MP and Iwata K (1997) Therapy of human carcinomas in athymic mice by inhibition of EGF receptor-mediated signal transduction with CP-358774: Pharmacodynamics of receptor inhibition and anti-tumor effects. Proc Am Assoc Cancer Res 38:633.
38. Prewett M, Rockwell P, Rose C and Goldstein NI (1996) Anti-tumor and cell cycle responses in KB cells treated with a chimeric anti-EGFr monoclonal antibody in combination with cisplatin. Int J Oncol 9:217-224.
39. Pustilnik LR, Neveu MJ, Arnold LD, Doty JL, McCarthy KE and Moyer JD (1997) Studies of the binding of the inhibitors to EGFr kinase by scintillation proximity assays. Proc Am Assoc Cancer Res 38:470.
40. Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z and Koprowski H (1987) Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunological mediated and effector cell-independent effects. Cancer Res 47:3692-3696.
41. Sainsbury JRC, Malcolm AJ, Appleton DR, Farndon JR and Harris AL (1985) Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 38:1225-1228.
42. Santon JB, Cronin MT, MacLeod CL, Mendelsohn J, Masui H and Gill GN (1986) Effects of epidermal growth factor receptor concentration on tumorigenicity of A431 cells in nude mice. Cancer Res 46:4701-4705.
43. Schnurch H-G, Stegmuller M, Vering A, Beckmann MW and Bender HG (1994) Growth inhibition of xenotransplanted human carcinomas by a monoclonal antibody directed against the epidermal growth factor receptor. Eur J Cancer 30: A491-A496.
44. Traxler PM (1998) Tyrosine kinase inhibitors in cancer treatment (oart II). Exp Opin Ther Patents (UK) 8:1599-1625.
45. Velu TJ (1990) Structure function and transforming potential of the epidermal growth factor receptor. Mol Cell Endocrinol 70:205-216.
46. Velu TJ, Beguinot L, Vass WC, Willingham MC, Merlino GT, Pastan I and Lowy DR (1987) Epidermal growth factor-dependent transformation by a human receptor proto-oncogene. Science (Wash DC) 238:1408-1410.
47. Vincent PW, Patmore SJ, Roberts BJ, Atkinson BE, Packard C, Lathia C, Leopold WR and Elliott WL (1998) Evaluation of EGF receptor family tyrosine kinase inhibitors with an ex vivo ELISA. Proc Am Assoc Cancer Res 39:315.
48. Wahl MI, Nishibe S, Kim JW, Kim H, Rhee SC and Carpenter G (1990) Identification of two epidermal growth factor-sensitive tyrosine phosphorylation sites of phospholipase C-gamma in intact HSC-1 cells. J Biol Chem 265:3944-3948.
49. Woodburn JR, Barker AJ, Gibson KH, Ashton SE, Wakeling AE, Curry BJ, Scarlett L and Henthorn LR (1997) ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proc Am Assoc Cancer Res 38:633.
50. Yang X-D, Jia X-C, Corvalan JRF, Wang P, Davis CG, and Jakobovits A (1999) Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59:1236-1243.
51. Yoneda T, Alsina MM, Watatani K, Bellot F, Schlessinger J and Mundy GR (1991a) Dependence of a human squamous carcinoma and associated paraneoplastic syndromes on the epidermal growth factor receptor pathway in nude mice. Cancer Res 51:2438-2443.
52. Yoneda T, Lyall RM, Alsina MM, Persons PE, Spada AP, Levitzki A, Zilberstein A and Mundy GR (1991b) The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res 51:4430-4435.